E-resources
-
Alberici, Federico; Delbarba, Elisa; Manenti, Chiara; Econimo, Laura; Valerio, Francesca; Pola, Alessandra; Maffei, Camilla; Possenti, Stefano; Piva, Simone; Latronico, Nicola; Focà, Emanuele; Castelli, Francesco; Gaggia, Paola; Movilli, Ezio; Bove, Sergio; Malberti, Fabio; Farina, Marco; Bracchi, Martina; Costantino, Ester Maria; Bossini, Nicola; Gaggiotti, Mario; Scolari, Francesco; Alberici, Federico; Delbarba, Elisa; Manenti, Chiara; Econimo, Laura; Valerio, Francesca; Pola, Alessandra; Maffei, Camilla; Possenti, Stefano; Zambetti, Nicole; Venturini, Margherita; Affatato, Stefania; Piarulli, Paola; Zappa, Mattia; Guerini, Alice; Boni, Francesca; Mucchetti, Alberto; Pezzini, Elena; Saccà, Chiara; Moscato, Marianna; Tonoli, Michela; Pasquali, Stefano; Viola, Fabio; Piva, Simone; Latronico, Nicola; Focà, Emanuele; Quiros-Roldan, Eugenia; Castelli, Francesco; Gaggia, Paola; Movilli, Ezio; Bove, Sergio; Malberti, Fabio; Farina, Marco; Bracchi, Martina; Costantino, Ester Maria; Bossini, Nicola; Gaggiotti, Mario; Scolari, Francesco
Kidney international reports, 05/2020, Volume: 5, Issue: 5Journal Article
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as coronavirus disease (COVID-19), is a major pandemic challenging health care systems around the world. The optimal management of patients infected with COVID-19 is still unclear, although the consensus is moving toward the need of a biphasic approach. During the first phase of the disease (from onset of the symptoms up to 7–10 days) viral-induced effects are prominent, with the opportunity to institute antiviral therapy. In the second inflammatory phase of the disease, immunosuppressive strategies (for example with glucocorticoids or anticytokine drugs) may be considered. This latter stage is characterized by the development of progressive lung involvement with increasing oxygen requirements and occasionally signs of the hemophagocytic syndrome. The management of the disease in patients with kidney disease is even more challenging, especially in those who are immunosuppressed or with severe comorbidities. Here we present the therapeutic approach used in Brescia (Italy) for managing patients infected with COVID-19 who underwent kidney transplantation and are receiving hemodialysis. Furthermore, we provide some clinical and physiopathological background, as well as preliminary outcome data of our cohort, to better clarify the pathogenesis of the disease and clinical management.
Author
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.